Loading...
Loading...
SCNI| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.2M |
| Operating Expense | 2.2M |
| Operating I/L | -2.4M |
| Other Income/Expense | 12.9M |
| Interest Income | 0.0M |
| Pretax | 10.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 10.5M |
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company based in Israel, specializing in the development, manufacturing, and commercialization of products for the prevention and treatment of infectious and autoimmune diseases. The company has a licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb), as well as for various other disease indications. With a focus on nanosized antibody technology, Scinai Immunotherapeutics generates revenue through the development and commercialization of NanoAbs for a range of disease indications, including COVID-19 and other infectious and autoimmune diseases.
